Sunday, July 09, 2017 5:15:05 PM
Obviously the ARS is our most likely catalyst. The ARS comparison between Neupogen and PLX was eased a lot when I saw Neupogen used 100% and 80% males in their trials. Unfair advantage as it was only the female NPH's that died with PLX. Out numbers would most likely been much higher using the same gender ratios they did. Looking forward to see what they are going to release later this month. Peeves me off that we have to wait that long. But hoping there is a reason for that.
Like Blue says, a couple more months will be telling. Something is brewing imo. Only thing is if it was big in nature, you would have thought something would get leaked somewhere. Hoping to see a significant uptick in volume, along with a little price gain in the next couple of weeks.
Last Shot Hydration Drink Announced as Official Sponsor of Red River Athletic Conference • EQLB • Jun 20, 2024 2:38 PM
ATWEC Announces Major Acquisition and Lays Out Strategic Growth Plans • ATWT • Jun 20, 2024 7:09 AM
North Bay Resources Announces Composite Assays of 0.53 and 0.44 Troy Ounces per Ton Gold in Trenches B + C at Fran Gold, British Columbia • NBRI • Jun 18, 2024 9:18 AM
VAYK Assembling New Management Team for $64 Billion Domestic Market • VAYK • Jun 18, 2024 9:00 AM
Fifty 1 Labs, Inc Announces Acquisition of Drago Knives, LLC • CAFI • Jun 18, 2024 8:45 AM
Hydromer Announces Attainment of ISO 13485 Certification • HYDI • Jun 17, 2024 9:22 AM